Cargando…

Bcl-xL activity influences outcome of the mitotic arrest

Microtubule-targeting (MT) drugs taxanes and vinca alkaloids are widely used as chemotherapeutic agents against different tumors for more than 30 years because of their ability to block mitotic progression by disrupting the mitotic spindle and activating the spindle assembly checkpoint (SAC) for a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Suleimenov, M., Bekbayev, S., Ten, M., Suleimenova, N., Tlegenova, M., Nurmagambetova, A., Kauanova, S., Vorobjev, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520339/
https://www.ncbi.nlm.nih.gov/pubmed/36188556
http://dx.doi.org/10.3389/fphar.2022.933112
_version_ 1784799602335023104
author Suleimenov, M.
Bekbayev, S.
Ten, M.
Suleimenova, N.
Tlegenova, M.
Nurmagambetova, A.
Kauanova, S.
Vorobjev, I.
author_facet Suleimenov, M.
Bekbayev, S.
Ten, M.
Suleimenova, N.
Tlegenova, M.
Nurmagambetova, A.
Kauanova, S.
Vorobjev, I.
author_sort Suleimenov, M.
collection PubMed
description Microtubule-targeting (MT) drugs taxanes and vinca alkaloids are widely used as chemotherapeutic agents against different tumors for more than 30 years because of their ability to block mitotic progression by disrupting the mitotic spindle and activating the spindle assembly checkpoint (SAC) for a prolonged period of time. However, responses to mitotic arrest are different—some cells die during mitotic arrest, whereas others undergo mitotic slippage and survive becoming able for proliferation. Using normal fibroblasts and several cancer cell types we determined two critical doses, T1 and T2, of mitotic inhibitors (nocodazole, Taxol, and vinorelbine). T1 is the maximal dose cells can tolerate undergoing normal division, and T2 is the minimal mitostatic dose, wherein > 90% of mitotic cells are arrested in mitosis. In all studied cell lines after treatment with mitotic inhibitors in a dose above T2 cells had entered mitosis either die or undergo mitotic slippage. We show that for all three drugs used cell death during mitotic arrest and after slippage proceeded via mitochondria-dependent apoptosis. We determined two types of cancer cells: sensitive to mitotic arrest, that is, undergoing death in mitosis (DiM) frequently, and resistant to mitotic arrest, that is, undergoing mitotic slippage followed by prolonged survival. We then determined that inhibition of Bcl-xL, but not other anti-apoptotic proteins of the Bcl-2 group that regulate MOMP, make resistant cells susceptible to DiM induced by mitotic inhibitors. Combined treatment with MT drugs and highly specific Bcl-xL inhibitors A-1155643 or A-1331852 allows achieving 100% DiM in a time significantly shorter than maximal duration of mitotic arrest in all types of cultured cells tested. We further examined efficacy of sequential treatment of cultured cells using mitotic inhibitors followed by inhibitors of Bcl-xL anti-apoptotic protein and for the first time show that sensitivity to Bcl-xL inhibitors rapidly declines after mitotic slippage. Thus sequential use of mitotic inhibitors and inhibitors of Bcl-xL anti-apoptotic protein will be efficient only if the Bcl-xL inhibitor will be added before mitotic slippage occurs or soon afterward. The combined treatment proposed might be an efficient approach to anti-cancer therapy.
format Online
Article
Text
id pubmed-9520339
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95203392022-09-30 Bcl-xL activity influences outcome of the mitotic arrest Suleimenov, M. Bekbayev, S. Ten, M. Suleimenova, N. Tlegenova, M. Nurmagambetova, A. Kauanova, S. Vorobjev, I. Front Pharmacol Pharmacology Microtubule-targeting (MT) drugs taxanes and vinca alkaloids are widely used as chemotherapeutic agents against different tumors for more than 30 years because of their ability to block mitotic progression by disrupting the mitotic spindle and activating the spindle assembly checkpoint (SAC) for a prolonged period of time. However, responses to mitotic arrest are different—some cells die during mitotic arrest, whereas others undergo mitotic slippage and survive becoming able for proliferation. Using normal fibroblasts and several cancer cell types we determined two critical doses, T1 and T2, of mitotic inhibitors (nocodazole, Taxol, and vinorelbine). T1 is the maximal dose cells can tolerate undergoing normal division, and T2 is the minimal mitostatic dose, wherein > 90% of mitotic cells are arrested in mitosis. In all studied cell lines after treatment with mitotic inhibitors in a dose above T2 cells had entered mitosis either die or undergo mitotic slippage. We show that for all three drugs used cell death during mitotic arrest and after slippage proceeded via mitochondria-dependent apoptosis. We determined two types of cancer cells: sensitive to mitotic arrest, that is, undergoing death in mitosis (DiM) frequently, and resistant to mitotic arrest, that is, undergoing mitotic slippage followed by prolonged survival. We then determined that inhibition of Bcl-xL, but not other anti-apoptotic proteins of the Bcl-2 group that regulate MOMP, make resistant cells susceptible to DiM induced by mitotic inhibitors. Combined treatment with MT drugs and highly specific Bcl-xL inhibitors A-1155643 or A-1331852 allows achieving 100% DiM in a time significantly shorter than maximal duration of mitotic arrest in all types of cultured cells tested. We further examined efficacy of sequential treatment of cultured cells using mitotic inhibitors followed by inhibitors of Bcl-xL anti-apoptotic protein and for the first time show that sensitivity to Bcl-xL inhibitors rapidly declines after mitotic slippage. Thus sequential use of mitotic inhibitors and inhibitors of Bcl-xL anti-apoptotic protein will be efficient only if the Bcl-xL inhibitor will be added before mitotic slippage occurs or soon afterward. The combined treatment proposed might be an efficient approach to anti-cancer therapy. Frontiers Media S.A. 2022-09-15 /pmc/articles/PMC9520339/ /pubmed/36188556 http://dx.doi.org/10.3389/fphar.2022.933112 Text en Copyright © 2022 Suleimenov, Bekbayev, Ten, Suleimenova, Tlegenova, Nurmagambetova, Kauanova and Vorobjev. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Suleimenov, M.
Bekbayev, S.
Ten, M.
Suleimenova, N.
Tlegenova, M.
Nurmagambetova, A.
Kauanova, S.
Vorobjev, I.
Bcl-xL activity influences outcome of the mitotic arrest
title Bcl-xL activity influences outcome of the mitotic arrest
title_full Bcl-xL activity influences outcome of the mitotic arrest
title_fullStr Bcl-xL activity influences outcome of the mitotic arrest
title_full_unstemmed Bcl-xL activity influences outcome of the mitotic arrest
title_short Bcl-xL activity influences outcome of the mitotic arrest
title_sort bcl-xl activity influences outcome of the mitotic arrest
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520339/
https://www.ncbi.nlm.nih.gov/pubmed/36188556
http://dx.doi.org/10.3389/fphar.2022.933112
work_keys_str_mv AT suleimenovm bclxlactivityinfluencesoutcomeofthemitoticarrest
AT bekbayevs bclxlactivityinfluencesoutcomeofthemitoticarrest
AT tenm bclxlactivityinfluencesoutcomeofthemitoticarrest
AT suleimenovan bclxlactivityinfluencesoutcomeofthemitoticarrest
AT tlegenovam bclxlactivityinfluencesoutcomeofthemitoticarrest
AT nurmagambetovaa bclxlactivityinfluencesoutcomeofthemitoticarrest
AT kauanovas bclxlactivityinfluencesoutcomeofthemitoticarrest
AT vorobjevi bclxlactivityinfluencesoutcomeofthemitoticarrest